期刊文献+

乙型肝炎病毒特异性细胞毒性T淋巴细胞应答与不同临床感染状态的关系 被引量:3

The association between antigen-specific cytotoxic lymphocytes response and different clinical status in patients with hepatitis B
原文传递
导出
摘要 目的分析人类白细胞抗原(HLA)-A0201限制性的特异性CTL,研究急性肝炎急性期和慢性乙型肝炎活动期患者T淋巴细胞对特异性抗原表位免疫应答的差异。方法收集HLA—A0201阳性的5例急性肝炎急性期和6例慢性乙型肝炎活动期患者的外周血单个核细胞(PBMc),酶联免疫斑点技术(EI,ISPOT)测定针对HBV聚合酶区(P01575—583)、包膜区(Env348—357)和核心区(Core18—27)3个CD8^+T淋巴细胞表位肽特异性CTL的数量和功能。数据采用t检验。结果经P01575583、Env348—357和Core18—27三条抗原肽刺激,急性乙型肝炎急性期患者组斑点形成细胞数(SFC)分别为110±13、165±17和185±20;慢性乙型肝炎活动期患者组SFC分别为22±4、23±5和30±5,两组差异有统计学意义(f值分别为10.9、15.2和8.0,均P〈0.05)。急性乙型肝炎急性期患者各抗原肽特异性CTL的应答能力P01575—583〈Env348—357〈Corel8-27,其中P01575—583和Core18-27比较,差异有统计学意义(t=4.0,P〈0.05),而Env348—357和Core18—27比较,差异无统计学意义(P〉0.05)。非特异性HLA-2402限制性Corell7-125刺激也出现SFC增加,但与阴性对照组比较,差异无统计学意义(P〉0.05)。结论急性感染者HBV特异性CTL应答水平显著高于慢性HBV感染者,慢性乙型肝炎患者体内的多克隆CTL数量和功能低下。 Objective To analyze human leucocyte antigen (HLA)-A0201 restricted antigenspecific cytotoxic lymphocytes (CTL), and to investigate the difference of T cell response to specific antigen epitopes between patients with acute phase of acute hepatitis B and active phase of chronic hepatitis B. Methods Peripheral blood mononuclear cells (PBMC) from 5 patients with acute phase of acute hepatitis B and 6 patients with active phase of chronic hepatitis B were isolated. The numbers and functions of CD8^+ T lymphocyte epitope peptide specific CTL were detected using enzyme-linked immunosorbent spot (EI.ISPOT) assay, and the 3 peptides were from HBV polymerase region (Po1575-583), envelope region (Env348-357) and core region (Core18-27), respectively. The data were analyzed using t test. Results The spot formation cell counts (SFC) of Po1575-583, Env348-357 and Core18-27 stimulations in patients with acute phase of acute hepatitis B were 110±13, 165 ±17 and 185 ± 20, respectively; and those in patients with active phase of chronic hepatitis B were 22 ± 4,23±5 and 30± 5, respectively; the differences were all significant (t = 10.9, 15.2 and 8.0, respectively, all P〈0.05). The CTL responses to the three peptides in patients with acute phase of acute hepatitis B were Po1575-583〈Env348 357〈Core18-27; and the difference between responses to Po1575-583 and Core18-27 was significant (t=4.0, P〈0. 05), while there was no statistical difference between CTL responses to Env348-357 and Corel8 27 (P〉0.05). The SFC were increased upon nonantigen specific HLA-A2404 restricted epitope (Core117-125), but the difference was not significant compared with negative control group (P 〉 0. 05). Conelusions Hepatitis B virus-specific CTL responses in patients with acute hepatitis B are significantly higher than those in patients with chronic hepatitis B. The number and function of polyclonal CTL are both impaired in patients with chronic hepatitis B.
出处 《中华传染病杂志》 CAS CSCD 北大核心 2009年第5期287-291,共5页 Chinese Journal of Infectious Diseases
基金 江苏省科教兴卫工程医学重点学科工程资助项目(200707) 江苏省卫生厅医学科技发展基金资助项目(H200311) 江苏省医学重点人才资金资助项目(RC2007049)
关键词 T淋巴细胞 细胞毒性 HLA抗原 肝炎 乙型 酶联免疫斑点技术 肝炎病毒 乙型 T lymphocytes, cytotoxic HLA antigens Hepatitis B Enzyme-linked immunosorbent spot Hepatitis B virus
  • 相关文献

参考文献4

二级参考文献33

共引文献14068

同被引文献22

  • 1Wang, Lu-Wen,Chen, Hui,Gong, Zuo-Jiong.High mobility group box-1 protein inhibits regulatory T cell immune activity in liver failure in patients with chronic hepatitis B[J].Hepatobiliary & Pancreatic Diseases International,2010,9(5):499-507. 被引量:23
  • 2王健,闵福援.乙肝病毒血清标志物的检测方法及其临床意义[J].中华检验医学杂志,2005,28(1):113-115. 被引量:96
  • 3Liang X, Bi S, Yang W,et al.Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47) :6550-6557.
  • 4Jeong SH.HBV infection as risk factor for non-Hodgkin lym- phoma[J].Lancet Oncol,2010,11 (9) :806-808.
  • 5Li X,Li G,Gao Z,et al.The relative frequencies of lymphoma subtypes in China:a nationwide study of 10002 cases by the Chinese lymphoma study group[J].Ann Oncol, 2011,22 (suppl 4):iv141.
  • 6Wang F, Xu RH,Han B,et al.High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lym- phoma compared with other cancers [J].Cancer,2007,109 (7) : 1360-1364.
  • 7Coiffier B,Thieblemont C,Van Den Neste E,et al.Long- term outcome of patients in the LNH-98.5 trial,the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients :a study by the grouped' Etudes des lymphomes de l' Aduhe [J].Blood, 2010, 116 (10) : 2040-2045.
  • 8European association for the study of the liver.EASL clin- ical practice guidelines :management of chronic hepatitis B virus infection[J].J Hepatol, 2012,57 ( 1 ) : 167-185.
  • 9Kim YM,Jeong SH,Kim JW,et al.Chronic hepatitis B, non-Hodgkin's lymphoma,and effect of prophylactic an- tiviral therapy[J].J Clin Virol, 2011,51 (4) : 241-245.
  • 10Lok AS,Liang RH,Chiu EK,et al.Reactivation of hepat- ictis B virus replica tion in patients receiving cytotoxic therapy.Report of a prospective study[J].Gastroenterology, 1991,100(1 ) : 182-188.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部